Institution
University of Bologna
Education•Bologna, Emilia-Romagna, Italy•
About: University of Bologna is a education organization based out in Bologna, Emilia-Romagna, Italy. It is known for research contribution in the topics: Population & Galaxy. The organization has 38387 authors who have published 115176 publications receiving 3460869 citations. The organization is also known as: Università di Bologna & UNIBO.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long- term outcomes among patients with newly diagnosed chronic-phase CML.
Abstract: Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. Methods In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. Results After a minimum follow-up of 12 months, the rate of confirmed complete cytogenetic response was higher with dasatinib than with imatinib (77% vs. 66%, P = 0.007), as was the rate of complete cytogenetic response observed on at least one assessment (83% vs. 72%, P = 0.001). The rate of major molecular response was higher with dasatinib than with imatinib (46% vs. 28%, P<0.0001), and responses were achieved in a shorter time with dasatinib (P<0.0001). Progression to the accelerated or blastic phase of CML occurred in 5 patients who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%). The safety profiles of the two treatments were similar. Conclusions Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.)
1,386 citations
••
Nicholas J Kassebaum1, Amelia Bertozzi-Villa1, Megan Coggeshall1, Katya Anne Shackelford1 +349 more•Institutions (179)
TL;DR: Global rates of change suggest that only 16 countries will achieve the MDG 5 target by 2015, with evidence of continued acceleration in the MMR, and MMR was highest in the oldest age groups in both 1990 and 2013.
1,383 citations
••
TL;DR: It is argued that chronic diseases are not only the result of ageing and inflammaging; these diseases also accelerate the ageing process and can be considered a manifestation of accelerated ageing, and the use of new biomarkers capable of assessing biological versus chronological age in metabolic diseases is proposed.
Abstract: Ageing and age-related diseases share some basic mechanistic pillars that largely converge on inflammation. During ageing, chronic, sterile, low-grade inflammation - called inflammaging - develops, which contributes to the pathogenesis of age-related diseases. From an evolutionary perspective, a variety of stimuli sustain inflammaging, including pathogens (non-self), endogenous cell debris and misplaced molecules (self) and nutrients and gut microbiota (quasi-self). A limited number of receptors, whose degeneracy allows them to recognize many signals and to activate the innate immune responses, sense these stimuli. In this situation, metaflammation (the metabolic inflammation accompanying metabolic diseases) is thought to be the form of chronic inflammation that is driven by nutrient excess or overnutrition; metaflammation is characterized by the same mechanisms underpinning inflammaging. The gut microbiota has a central role in both metaflammation and inflammaging owing to its ability to release inflammatory products, contribute to circadian rhythms and crosstalk with other organs and systems. We argue that chronic diseases are not only the result of ageing and inflammaging; these diseases also accelerate the ageing process and can be considered a manifestation of accelerated ageing. Finally, we propose the use of new biomarkers (DNA methylation, glycomics, metabolomics and lipidomics) that are capable of assessing biological versus chronological age in metabolic diseases.
1,380 citations
••
TL;DR: Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing has a higher predictive value than echocardiography alone.
1,372 citations
••
Katholieke Universiteit Leuven1, University of Sheffield2, Medical University of Vienna3, Charité4, University of Bologna5, Vita-Salute San Raffaele University6, University of Manchester7, University of Lugano8, Netherlands Cancer Institute9, Monash University10, St James's University Hospital11, Erasmus University Medical Center12, University of Aberdeen13, Aberdeen Royal Infirmary14, Wrightington, Wigan and Leigh NHS Foundation Trust15, Cardiff University16, University of Amsterdam17, University of Lyon18, Utrecht University19, University of Liverpool20
TL;DR: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa guidelines summarise the most recent findings and advice for their use in clinical practice and include a strong recommendation to consider moderate hypofractionation in intermediate-risk patients.
1,369 citations
Authors
Showing all 39076 results
Name | H-index | Papers | Citations |
---|---|---|---|
Anil K. Jain | 183 | 1016 | 192151 |
H. S. Chen | 179 | 2401 | 178529 |
Stefan Schreiber | 178 | 1233 | 138528 |
Alvio Renzini | 162 | 908 | 95452 |
David H. Adams | 155 | 1613 | 117783 |
Roberto Romero | 151 | 1516 | 108321 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Paolo Boffetta | 148 | 1455 | 93876 |
Kypros H. Nicolaides | 147 | 1302 | 87091 |
J. Fraser Stoddart | 147 | 1239 | 96083 |
Fabio Finelli | 147 | 542 | 111128 |
Jack Hirsh | 146 | 734 | 86332 |
Kjell Fuxe | 142 | 1479 | 89846 |
Andrew Ivanov | 142 | 1812 | 97390 |
Peter Lang | 140 | 1136 | 98592 |